JG
PTCT icon

Joel Greenblatt’s PTC Therapeutics PTCT Stock Holding History

Joel Greenblatt’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,259
Closed -$1.24M – 1838
2025
Q4 		$1.24M Sell
16,259
-1,797
-10% -$131K ﹤0.01% 1198
2025
Q3 		$1.11M Sell
18,056
-17,573
-49% -$915K ﹤0.01% 1168
2025
Q2 		$1.74M Buy
35,629
+30,829
+642% +$1.46M 0.01% 969
2025
Q1 		$245K Buy
+4,800
New +$240K ﹤0.01% 1425
2024
Q2 		– Sell
-7,527
Closed -$219K – 1481
2024
Q1 		$219K Buy
+7,527
New +$211K ﹤0.01% 1273
2023
Q3 		– Sell
-6,781
Closed -$276K – 1399
2023
Q2 		$276K Sell
6,781
-5,536
-45% -$271K 0.01% 1145
2023
Q1 		$597K Buy
12,317
+5,512
+81% +$252K 0.01% 893
2022
Q4 		$260K Sell
6,805
-250
-4% -$10.4K 0.01% 1071
2022
Q3 		$354K Buy
7,055
+456
+7% +$22.3K 0.01% 938
2022
Q2 		$264K Buy
+6,599
New +$231K 0.01% 971
2021
Q3 		– Sell
-4,785
Closed -$202K – 1101
2021
Q2 		$202K Hold
4,785
– – 0.01% 951
2021
Q1 		$227K Sell
4,785
-1
-0% -$59 0.01% 919
2020
Q4 		$292K Sell
4,786
-333
-7% -$19.6K 0.01% 841
2020
Q3 		$239K Hold
5,119
– – 0.01% 890
2020
Q2 		$260K Sell
5,119
-51
-1% -$2.51K 0.01% 894
2020
Q1 		$231K Buy
5,170
+37
+0.7% +$1.86K 0.01% 904
2019
Q4 		$247K Buy
+5,133
New +$218K ﹤0.01% 994
2019
Q3 		– Sell
-5,133
Closed -$231K – 1194
2019
Q2 		$231K Buy
+5,133
New +$203K ﹤0.01% 1026
2019
Q1 		– Sell
-11,079
Closed -$380K – 1222
2018
Q4 		$380K Sell
11,079
-1,761
-14% -$63.3K 0.01% 816
2018
Q3 		$603K Buy
12,840
+689
+6% +$28.5K 0.01% 702
2018
Q2 		$410K Buy
+12,151
New +$379K 0.01% 730
2017
Q4 		– Sell
-19,796
Closed -$396K – 1038
2017
Q3 		$396K Buy
+19,796
New +$388K 0.01% 744

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Joel Greenblatt's PTCT Position: Q1 2026 in Review

Joel Greenblatt sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 16,259 shares — an estimated $1.24M sold.

Joel Greenblatt first reported a position in PTCT in Q3 2017 and held it in 22 quarters. The position peaked at $1.74M in Q2 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Joel Greenblatt reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Joel Greenblatt sold 16,259 PTC Therapeutics shares in Q1 2026, an estimated $1.24M.
  • Joel Greenblatt first reported a position in PTC Therapeutics in Q3 2017 and held it in 22 quarters.
  • Joel Greenblatt's PTC Therapeutics position peaked at $1.74M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.